摘要
目的观察重组人干扰素α-1b联合热毒宁治疗呼吸道合胞病毒感染肺炎的疗效,并探讨其对患儿血清降钙素原(PCT)、C反应蛋白(CRP)及炎症因子水平的影响。方法选择2018年3月至2019年2月在开平市中心医院儿科接受治疗的98例呼吸道合胞病毒感染肺炎患儿进行研究,按照随机数表法分为观察组和对照组,每组49例。对照组患儿给予重组人干扰素α-1b治疗,观察组患儿采用重组人干扰素α-1b联合热毒宁治疗,疗程均为1周。比较两组患儿的治疗效果、症状体征消失时间、治疗前后的血清PCT、CRP、炎症因子白细胞介素-1(IL-1)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF-α)水平及不良反应情况。结果观察组患儿的治疗总有效率为93.88%,明显高于对照组的78.72%,差异有统计学意义(P<0.05);观察组患儿的呼吸困难、咳嗽、喘鸣音消失时间分别为(1.59±0.32)d、(3.90±0.87)d、(3.21±0.86)d,明显短于对照组的(3.68±0.75)d、(6.58±1.23)d、(5.79±2.06)d,差异均具有统计学意义(P<0.05);治疗后,观察组患儿的血清PCT、CRP水平分别为(0.11±0.03)ng/mL、(3.79±0.38)mg/L,明显低于对照组的(0.23±0.06)ng/mL、(4.89±0.56)mg/L,差异均具有统计学意义(P<0.05);治疗后,观察组患儿的IL-1、IL-6、TNF-α水平、核因子κB(NF-κB)水平分别为(87.12±3.72)pg/mL、(97.02±3.05)pg/mL、(86.52±3.27)ng/mL、(5.07±1.32)ng/mL,明显低于对照组的(109.76±5.21)pg/mL、(109.86±6.23)pg/mL、(98.79±5.36)ng/mL、(6.89±1.86)ng/mL,差异均具有统计学意义(P<0.05);两组患儿的不良反应发生率比较差异无统计学意义(P>0.05)。结论重组人干扰素α-1b联合热毒宁治疗呼吸道合胞病毒感染肺炎可改善患儿的临床症状及体征,降低血清PCT、CRP水平,抑制炎症因子表达,安全可靠,治疗效果显著。
Objective To study the effect of recombinant human interferonα-1b combined with Reduning on children with respiratory syncytial virus infection pneumonia and its influence on serum procalcitonin(PCT),C-reactive protein(CRP),and inflammatory factors.Methods Ninety-eight children with respiratory syncytial virus infection pneumonia who received treatment in Kaiping Central Hospital from March 2018 to February 2019 were selected for this study.According to the simple drawing of lots,they were divided into study group(n=49)and control group(n=49).The control group was treated with recombinant human interferonα-1b,and the study group was treated with recombinant human interferonα-1b combined with Reduning.The treatment course of both groups lasted 1 week.The curative effect,disappearance time of symptoms and signs,changes of serum PCT,CRP,inflammatory factors interleukin-1(IL-1),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and adverse reactions were compared between the two groups.Results After treatment,the total effective rate of the study group was 93.88%,significantly higher than 78.72%of the control group(P<0.05).The disappeared time of dyspnea,cough,wheezing in the study group were(1.59±0.32)d,(3.90±0.87)d,(3.21±0.86)d,significantly shorter than(3.68±0.75)d,(6.58±1.23)d,(5.79±2.06)d in the control group(P<0.05);the serum PCT,CRP levels of the study group were(0.11±0.03)ng/mL,(3.79±0.38)mg/L,significantly lower than(0.23±0.06)ng/mL,(4.89±0.56)mg/L in the control group(P<0.05).Levels of IL-1,IL-6,TNF-α,NF-κB in the study group were(87.12±3.72)pg/mL,(97.02±3.05)pg/mL,(86.52±3.27)ng/mL,(5.07±1.32)ng/mL,significantly lower than(109.76±5.21)pg/mL,(109.86±6.23)pg/mL,(98.79±5.36)ng/mL,(6.89±1.86)ng/mL in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Recombinant human interferonα-1b combined with Reduning in the treatment of respiratory syncytial virus infection can improve the clinical symptoms
作者
陈清凤
蔡锋铭
余洽超
周逢洽
CHEN Qing-feng;CAI Feng-ming;YU Qia-chao;ZHOU Feng-qia(Department of Pediatrics,Kaiping Central Hospital,Kaiping 529300,Guangdong,CHINA)
出处
《海南医学》
CAS
2021年第11期1438-1441,共4页
Hainan Medical Journal
关键词
重组人干扰素Α-1B
热毒宁
呼吸道合胞病毒感染肺炎
疗效
降钙素原
C反应蛋白
炎症因子
不良反应
Recombinant human interferonα-1b
Reduning
Respiratory syncytial virus infection pneumonia
Therapeutic effect
Procalcitonin(PCT)
C-reactive protein(CRP)
Inflammatory factors
Adverse reactions
